New research identifies potential new TED biomarkers based on the disease activity or inactivity.

Though rare, visual decreases can occur within 1 day postoperatively after phacoemulsification surgery.

Over the years, IKA has become an invaluable resource for eye care professionals.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular surface.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

The patented AR lens coating creates thinner, stronger lenses than the alternative, and is now available to patients who love Transitions lenses.

The lens giant pairs precision vision of freeform-optimized lenses with the cost benefit of standard single vision lenses.

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

The 'Screen, Protect, Cure' campaign aims to education individuals who may be at risk for glaucoma, while raising funding for glaucoma research during Glaucoma Awareness Month.

One individual’s habit can be the demise of good health.

A multicenter US study revealed that the long-term use of metformin to treat diabetes and lifestyle changes in patients with diabetes were not associated with the risk of age-related macular degeneration (AMD).

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

Lessons can be learned from each patient experience, even the strange ones.

Leo Semes, OD, FAAO, shares key highlights from his EyeCon 2022 presentation, "Advances in therapies for retinal disease."

As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

A meditation on the effects of putting off doctors' orders.

An increase in screen time has led to a rise in binocular vision disorders.

Look out for at-risk patients and prepare to establish treatment protocols.

In the second deal between Harrow and Novartis, the former is expected to add 5 ophthalmic products to its portfolio.